Literature DB >> 17631293

Caldesmon suppresses cancer cell invasion by regulating podosome/invadopodium formation.

T Yoshio1, T Morita, Y Kimura, M Tsujii, N Hayashi, K Sobue.   

Abstract

The podosome and invadopodium are dynamic cell-adhesion structures that degrade the extracellular matrix (ECM) and promote cell invasion. We recently reported that the actin-binding protein caldesmon is a pivotal regulator of podosome formation. Here, we analyzed the caldesmon's involvement in podosome/invadopodium-mediated invasion by transformed and cancer cells. The ectopic expression of caldesmon reduced the number of podosomes/invadopodia and decreased the ECM degradation activity, resulting in the suppression of cell invasion. Conversely, the depletion of caldesmon facilitated the formation of podosomes/invadopodia and cell invasion. Taken together, our results indicate that caldesmon acts as a potent repressor of cancer cell invasion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631293     DOI: 10.1016/j.febslet.2007.06.073

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  36 in total

1.  Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.

Authors:  Dennis J O'Rourke; Daniel A DiJohnson; Robert J Caiazzo; James C Nelson; David Ure; Michael P O'Leary; Jerome P Richie; Brian C-S Liu
Journal:  Clin Chim Acta       Date:  2011-11-29       Impact factor: 3.786

2.  Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development.

Authors:  Todd M Pitts; Aik Choon Tan; Gillian N Kulikowski; John J Tentler; Amy M Brown; Sara A Flanigan; Stephen Leong; Christopher D Coldren; Fred R Hirsch; Marileila Varella-Garcia; Christopher Korch; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

3.  Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion.

Authors:  Utpal K Mukhopadhyay; Patrick Mooney; Lilly Jia; Robert Eves; Leda Raptis; Alan S Mak
Journal:  Mol Cell Biol       Date:  2010-08-23       Impact factor: 4.272

4.  A cell-based high-content screening assay reveals activators and inhibitors of cancer cell invasion.

Authors:  Manuela Quintavalle; Leonardo Elia; Jeffrey H Price; Susanne Heynen-Genel; Sara A Courtneidge
Journal:  Sci Signal       Date:  2011-07-26       Impact factor: 8.192

Review 5.  Diversification of caldesmon-linked actin cytoskeleton in cell motility.

Authors:  Taira Mayanagi; Kenji Sobue
Journal:  Cell Adh Migr       Date:  2011-03-01       Impact factor: 3.405

6.  cGMP-dependent protein kinase Iβ regulates breast cancer cell migration and invasion via interaction with the actin/myosin-associated protein caldesmon.

Authors:  Raphaela Schwappacher; Hema Rangaswami; Jacqueline Su-Yuo; Aaron Hassad; Ryan Spitler; Darren E Casteel
Journal:  J Cell Sci       Date:  2013-02-15       Impact factor: 5.285

Review 7.  Caldesmon as a therapeutic target for proliferative vascular diseases.

Authors:  Chi-Ming Hai
Journal:  Mini Rev Med Chem       Date:  2008-10       Impact factor: 3.862

8.  Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.

Authors:  Bart M Maślikowski; Benjamin D Néel; Ying Wu; Lizhen Wang; Natalie A Rodrigues; Germain Gillet; Pierre-André Bédard
Journal:  BMC Cancer       Date:  2010-02-12       Impact factor: 4.430

9.  Caldesmon regulates the motility of vascular smooth muscle cells by modulating the actin cytoskeleton stability.

Authors:  Qifeng Jiang; Renjian Huang; Shaoxi Cai; Chih-Lueh A Wang
Journal:  J Biomed Sci       Date:  2010-02-03       Impact factor: 8.410

10.  Identification of a tumor microenvironment-associated prognostic gene signature in bladder cancer by integrated bioinformatic analysis.

Authors:  Zhengchun Liu; Xiuli Liu; Rui Cai; Meilian Liu; Rensheng Wang
Journal:  Int J Clin Exp Pathol       Date:  2021-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.